DAX24.490 +0,6%Est505.791 -0,1%MSCI World4.343 -0,1%Top 10 Crypto11,63 -0,5%Nas23.349 -0,3%Bitcoin74.692 -0,8%Euro1,1735 -0,1%Öl61,27 -1,0%Gold4.323 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 DroneShield A2DMAA Bayer BAY001 Deutsche Telekom 555750 Novo Nordisk A3EU6F Lufthansa 823212 Allianz 840400 Infineon 623100 Tesla A1CX3T Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Amazon 906866 BYD A0M4W9
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet letzten Handelstag 2025 freundlich -- Rheinmetall, RENK, HENSOLDT & TKMS: Putin wirft Ukraine Terror vor -- TUI, Palantir, Meta im Fokus
Top News
ETF-Depot eröffnen: Was Anleger vor dem ersten Kauf wissen sollten ETF-Depot eröffnen: Was Anleger vor dem ersten Kauf wissen sollten
Interview: Carmignac Sécurité - In allen Marktphasen stabile Erträge mit begrenzter Volatilität Interview: Carmignac Sécurité - In allen Marktphasen stabile Erträge mit begrenzter Volatilität
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Travere Thereapeutics Aktie

Kaufen
Verkaufen
33,00 EUR -0,20 EUR -0,60 %
BER
38,52 USD +0,85 USD +2,26 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.2,96 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2QHYP

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS89422G1076

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTVTX

Travere Thereapeutics Aktien News

DatumMeistgelesen
PR NewswireCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireTVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR NewswireTVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Travere Thereapeutics News

Travere Thereapeutics News: auf dieser Seite finden Sie alle Travere Thereapeutics News und Nachrichten zur Travere Thereapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Travere Thereapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Travere Thereapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.